Abstract
Several discoveries have paved the way to personalise cancer medicine and a tremendous gain of knowledge in genomics and molecular mechanisms of cancer progression cumulated over the last years. Big stories in biology commonly start in a simple model system. No wonder microRNAs have been identified as regulators of embryonic development in the nematode Caenorhabditis elegans. From the first identification in worms to the first-in-man microRNA-based clinical trial in humans, almost 20 years passed. In this review we follow the story of understanding microRNA alterations in cancer, describe recent developments in the microRNA field and critically discuss their potential as diagnostic, prognostic and therapeutics factors in cancer medicine. We will explain the rationale behind the use of microRNAs in cancer diagnosis and prognosis prediction, but also discuss the limitations and pitfalls associated with this. Novel developments of combined microRNA/siRNA pharmacological approaches will be discussed and most recently data about MXR34, the first-tested microRNA drug will be described.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 569-573 |
| Number of pages | 5 |
| Journal | British journal of cancer |
| Volume | 113 |
| Issue number | 4 |
| DOIs | |
| State | Published - Aug 11 2015 |
Keywords
- cancer
- diagnosis
- microRNAs
- prognosis
- treatment
- worms
ASJC Scopus subject areas
- Oncology
- Cancer Research